Comparison of mutant frequencies and types of mutations induced by thiotepa in the endogenous Hprt gene and transgenic lacI gene of Big Blueρ rats

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 403, Issue 1-2, 1998, Pages 199-214

  Chen, Tao ^a   Aidoo, Anane ^a   Manjanatha, Mugimane G ^a   Mittelstaedt, Roberta A ^a   Shelton, Sharon D ^a   Lyn Cook, Lascelles E ^a   Casciano, Daniel A ^a   Heflich, Robert H ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

CpG site; Lymphocyte; Multiplex polymerase chain reaction; Reverse transcriptase polymerase chain reaction; Transcription coupled DNA repair; Transgene

Indexed keywords

CELL DNA; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; THIOTEPA;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MUTAGENESIS; CONTROLLED STUDY; DNA REPAIR; FRAMESHIFT MUTATION; GENE DELETION; LYMPHOCYTE; MUTATION RATE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; TRANSGENE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BACTERIAL PROTEINS; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DNA, COMPLEMENTARY; DNA, RECOMBINANT; ESCHERICHIA COLI PROTEINS; GENES, BACTERIAL; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INTRONS; LYMPHOCYTES; MALE; MOLECULAR SEQUENCE DATA; MUTAGENS; MUTATION; POINT MUTATION; POLYMERASE CHAIN REACTION; RATS; RATS, INBRED F344; REPRESSOR PROTEINS; THIOTEPA;

ANIMALIA;

EID: 0032541153     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00080-3     Document Type: Article

References (50)

1. [1] S.W. Kohler, G.S. Provost, A. Fieck, P.L. Kretz, W.O. Bullock, J.A. Sorge, D.L. Putman, J.M. Short, Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice, Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 7958-7962.
2. [2] G.S. Provost, P.L. Kretz, R.T. Hamner, C.D. Matthews, B.J. Rogers, K.S. Lundberg, M.J. Dycaico, J.M. Short, Transgenic systems for in vivo mutation analysis, Mutat. Res. 288 (1993) 133-149.
3. [3] K.S. Tao, C. Urlando, J.A. Heddle, Comparison of somatic mutation in a transgenic versus host locus, Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 10681-10685.
4. [4] T.R. Skopek, K.L. Kort, D.R. Marino, Relative sensitivity of the endogenous hprt gene and lacI transgene in ENU-treated Big Blue™ B6C3F1 mice, Environ. Mol. Mutagen. 26 (1995) 9-15.
5. [5] V.E. Walker, N.J. Gorelick, J.L. Andrews, T.R. Craft, J.G. deBoer, B.W. Glickman, T.R. Skopek, Frequency and spectrum of ethylnitrosourea-induced mutation at the hprt and lacI loci in splenic lymphocytes of exposed lacI transgenic mice, Cancer Res. 56 (1996) 4654-4661.
6. [6] T.R. Skopek, K.L. Kort, D.R. Marino, L.V. Mittal, D.R. Umbenhauer, G.M. Laws, S.P. Adams, Mutagenic response of the endogenous hprt gene and lacI transgene in benzo[a]pyrene-treated Big Blue™ B6C3F1 mice, Environ. Mol. Mutagen. 28 (1996) 376-384.
7. [7] M.G. Manjanatha, S.D. Shelton, A. Aidoo, L.E. Lyn-Cook, D.A. Casciano, Comparison of in vivo mutagenesis in the endogenous hprt gene and the lacI transgene of Big Blue® rats treated with 7.12-dimethylbenz[a]anthracene, Mutat. Res. 401 (1998) 165-178.
8. [8] J.L. Andrews, V.E. Walker, P.B. Upton, J.G. deBoer, N.J. Gorelick, Cyclophosphamide-induced mutations are detected at the Hprt but not the lacI loci in splenic T-cells of exposed Big Blue® mice, Environ. Mol. Mutagen. 27 (1996) 4, Suppl. 27.
9. [9] S.C. Sisk, L.J. Pluta, K.G. Meyer, B.C. Wong, L. Recio, Assessment of the in vivo mutagenicity of ethylene oxide in the tissues of B6C3F1 lacI transgenic mice following inhalation exposure, Mutat. Res. 391 (1997) 153-164.
10. [10] V.E. Walker, S.C. Sisk, P.B. Upton, B.A. Wong, L. Recio, In vivo mutagenicity of ethylene oxide at the hprt locus in T-lymphocytes of B6C3F1 lacI transgenic mice following inhalation exposure, Mutat. Res. 392 (1997) 211-222.
11. [11] R.A. Mittelstaedt, M.G. Manjanatha, S.D. Shelton, L.E. Lyn-Cook, J.B. Chen, A. Aidoo, D.A. Casciano, R.H. Heflich, Comparison of the types of mutations induced by 7,12-dimethylbenz[a]anthracene in the lacI and hprt genes of Big Blue® rats, Environ. Mol. Mutagen. 31 (1998) 149-156.
12. [12] T. Chen, A. Aidoo, R.A. Mittelstaedt, D.A. Casciano, R.H. Heflich, Hprt mutant frequency and molecular analysis of Hprt mutations in Fischer 344 rats treated with carcinogenic doses of thiotepa, submitted.
13. [13] S. Farber, R. Appleton, V. Downing, F. Heald, J. King, R. Toch, Clinical studies on the carcinolytic action of triethylenephosphoramide, Cancer 6 (1953) 135-141.
14. [14] G.D. Stoner, M.B. Shimkin, A.J. Kniazeff, J.H. Weisburger, E.K. Weisburger, G.B. Gori, Test for carcinogenicity of food additives and chemotherapeutic agents by the pulmonary tumor response in strain A mice, Cancer Res. 33 (1973) 3069-3085.
15. [15] National Cancer Institute, Bioassay of thiotepa for possible carcinogenicity, Tech. Rep. Ser. No. 58; DHEW Publ. No. (NIH) 78-1308, US Government Printing Office, Washington, DC, 1978.
16. [16] IARC, Thiotepa, in: Pharmaceutical Drugs, Vol. 50, IARC, Lyon, 1990, pp. 123-141.
17. [17] T.G. Selezneva, N.P. Korman, Analysis of chromosomes of somatic cells in patients treated with antitumor drugs, Sov. Genet. 9 (1973) 1575-1579.
18. [18] A.M. Malashenko, N.I. Surkova, Mutagenic effect of thioTEPA in laboratory mice. V. Influence of female genotype on realization of dominant lethal mutations induced in the spermatids of males, Genetika 11 (1975) 105-111.
19. 1)C1-3 cells by cancer chemotherapeutic agents, Cancer Res. 37 (1977) 2202-2208.
20. [20] K.K. Semenov, A.M. Malashenko, Appearance of dominant lethal mutations during early embryogenesis of the mouse, Sov. Genet. 17 (1981) 309-313.
21. [21] N.P. Bochkov, S.V. Stukalov, A.N. Chebotarev, Comparison of the frequency of chromosomal aberrations induced by thiophosphamide in rabbit lymphocytes in vitro and in vivo, Bull. Exp. Biol. Med. 94 (1982) 1118-1121.
22. [22] K.N. Yakovenko, S.A. Kagramanyan, Combined action of thiophosphamide and dipin on chromosomes of human lymphocytes, Cytol. Genet. 11 (1982) 53-56.
23. [23] E.G. Shcheglova, A.N. Chebotarev, Comparison of level of sister chromatid exchanges and chromosomal aberrations induced by chemical mutagens in vitro, Bull. Exp. Biol. Med. 96 (1983) 1604-1606.
24. [24] S.M. Kuzin, S.V. Stukalov, P.G. Popandopulo, Quantitative comparison of the cytogenetic effect of thiophosphamide on monkey lymphocytes in vivo and in vitro, Bull. Exp. Biol. Med. 103 (1987) 394-396.
25. [25] W.F. Benedict, M.S. Baker, L. Haroun, E. Choi, B.N. Ames, Mutagenicity of cancer chemotherapeutic agents in the Salmonella/microsome test, Cancer Res. 37 (1977) 2209-2213.
26. [26] Y.V. Paschin, V.I. Kozachenko, The modifying effect of hexavalent chromate on the mutagenic activity of thio-TEPA, Mutat. Res. 103 (1982) 367-370.
27. [27] A. Aidoo, L.E. Lyn-Cook, R.A. Mittelstaedt, R.H. Heflich, D.A. Casciano, Induction of 6-thioguanine-resistant lymphocytes in Fischer 344 rats following in vivo exposure to N-ethyl-N-nitrosourea and cyclophosphamide, Environ. Mol. Mutagen. 17 (1991) 141-151.
28. [28] A. Aidoo, L.E. Lyn-Cook, R.H. Heflich, E.O. George, D.A. Casciano, The effect of time after treatment, treatment schedule and animal age on the frequency of 6-thioguanine-resistant T-lymphocytes induced in Fischer 344 rats by N-ethyl-N-nitrosourea, Mutat. Res. 298 (1993) 169-178.
29. [29] B.J. Rogers, G.S. Provost, R.R. Young, D.L. Putman, J.M. Short, Intralaboratory optimization and standardization of mutant screening conditions used for a lambda/lacI transgenic mouse mutagenesis assay (I), Mutat. Res. 327 (1995) 57-66.
30. [30] T. Chen, R.A. Mittelstaedt, R.H. Heflich, Multiplex PCR for the analysis of deletion mutation in the rat lymphocyte hprt assay, Environ. Mol. Mutagen. 29 (1997) 9, Suppl. 28.
31. [31] T. Chen, A. Aidoo, D.A. Casciano, R.H. Heflich, Expansion of rat 6-thioguanine-resistant T-lymphocyte clones by stimulation with ionomycin and a phorbol ester, Environ. Mol. Mutagen. 31 (1998) 97-102.
32. [32] M.G. Manjanatha, J.B. Chen, J.G. Shaddock Jr., A.J. Harris, S.D. Shelton, D.A. Casciano, Molecular analysis of lacI mutations in Rat2™ cells exposed to 7,12-dimethylbenz[a]anthracene: evidence for DNA sequence and DNA strand biases for mutation, Mutat. Res. 372 (1996) 53-64.
33. [33] H.L. Erfle, D.F. Walsh, J. Holcroft, N. Hague, J.G. de Boer, B.W. Glickman, An efficient laboratory protocol for the sequencing of large numbers of lacI mutants recovered from Big Blue® transgenic animals, Environ. Mol. Mutagen. 28 (1996) 393-396.
34. [34] N.F. Cariello, W.W. Piegorsch, W.T. Adams, T.R. Skopek, Computer program for the analysis of mutational spectra: application to p53 mutations, Carcinogenesis 15 (1994) 2281-2285.
35. [35] G.R. Stuart, N.J. Gorelick, J.L. Andrews, J.G. de Boer, B.W. Glickman, The genetic analysis of lacI mutations in sectored plaques from Big Blue® transgenic mice, Environ. Mol. Mutagen. 28 (1996) 385-392.
36. [36] R.M. Schaaper, B.N. Danforth, B.W. Glickman, Mechanisms of spontaneous mutagenesis: an analysis of the spectrum of spontaneous mutation in the Escherichia coli lacI gene, J. Mol. Biol. 189 (1986) 273-284.
37. [37] R.A. Mittelstaedt, M.G. Manjanatha, S. Shelton, T. Chen, D.A. Casciano, R.H. Heflich, Spontaneous mutation in the splenocytes of transgenic Big Blue® rats, Environ. Mol. Mutagen. 31 (1998) 11, Suppl. 29.
38. [38] T.R. Skopek, Of mice and mutants: target size and sensitivity, Mutat. Res. 331 (1995) 225-228.
39. [39] M.J. Dycaico, G.S. Provost, P.L. Kretz, S.L. Ransom, J.C. Moores, J.M. Short, The use of shuttle vectors for mutation analysis in transgenic mice and rats, Mutat. Res. 307 (1994) 461-478.
40. [40] J.A. Gossen, H.-J. Martus, J.Y. Wei, J. Vijg, Spontaneous and X-ray-induced deletion mutations in a LacZ plasmid-based transgenic mouse model, Mutat. Res. 331 (1995) 89-97.
41. [41] V.L. Buettner, H. Nishino, S.S. Sommer, Large deletion detected with the Big Blue® transgenic mouse mutagenesis assay, Mutat. Res. 361 (1996) 187-189.
42. [42] S.W. Kohler, G.S. Provost, A. Fieck, P.L. Kretz, W.O. Bullock, D.L. Putman, J.A. Sorge, J.M. Short, Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP /lacI shuttle vector, Environ. Mol. Mutagen. 18 (1991) 316-321.
43. [43] B.S. Shane, J.G. de Boer, B.W. Glickman, K.R. Tindall, Mutation spectrum of benzo[a]pyrene in the liver of C57BL/6 Big Blue® mice, Environ. Mol. Mutagen. 27 (1996) 62, Suppl. 27.
44. [44] P.J. Farabaugh, Sequence of the lacI gene, Nature 274 (1978) 765-769.
45. [45] S.W. Kohler, G.S. Provost, P.L. Kretz, M.J. Dycaico, J.A. Sorge, J.M. Short, Development of a short-term, in vivo mutagenesis assay: the effects of methylation on the recovery of a lambda phage shuttle vector from transgenic mice, Nucleic Acids Res. 18 (1990) 3007-3013.
46. [46] S.M. Musser, S.-S. Pan, M.J. Egorin, D.J. Kyle, P.S. Gallery, Alkylation of DNA with aziridine produced during the hydrolysis of N,N′,N″-triethylenethiophosphoramide, Chem. Res. Toxicol. 5 (1992) 95-99.
47. [47] I. Mellon, G. Spivak, P.C. Hanawalt, Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene, Cell 51 (1987) 241-249.
48. [48] P.C. Hanawalt, Preferential repair of damage in actively transcribed DNA sequences in vivo, Genome 31 (1989) 605-611.
49. [49] J.G. Jansen, H. Vrieling, A.A. van Zeeland, G.R. Mohn, The gene encoding hypoxanthine-guanine phosphoribosyltransferase as target for mutational analysis: PCR cloning and sequencing of the cDNA from the rat, Mutat. Res. 266 (1992) 105-116.
50. [50] T. Chen, R.A. Mittelstaedt, R.H. Heflich, DNA sequence flanking the protein coding regions of the rat Hprt gene, Mutat. Res. 382 (1998) 79-80.